Key facts
- It has raised $32.7M; the latest was Later Stage VC ($10.3M) in Mar 2026.
- Notable investors include Tech Incubator Program for Startup, KB Investment, Korea Technology Finance, Murex Partners, Premier Partners — 12 tracked in total.
- Connext has filed 2 Form Ds with the SEC since 2017, most recently Feb 2021 ($3.6M sold to 11 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Connext
- ·The full record, as it builds
Funding rounds
No funding rounds for Connext are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Connext
Developer of regenerative medicine technologies and products intended to develop treatments for rare diseases. The company commercializes specialty biopharmaceuticals through linkage and innovation based on its chemistry, manufacturing, and controls capabilities, based on recombinant microorganisms, enabling doctors to expand indications to cover a wide range of diseases in the areas of oncology and dermatology.
- Sector
- Healthcare
- HQ
- Daegu, South Korea
- Founded
- 2017
- Employees
- 18
- Website
- connext.co.kr/
- Ownership
- Privately Held (backing)
Connext doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Connext shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Connext in its N-PORT filings yet. We sweep new filings monthly.